SBIR Phase I: Biotransformable Block Terpolymers for Drug-Eluting Stents

这项小企业创新研究（SBIR）一期研究项目旨在开发一种用于药物洗脱冠状动脉支架（DES）的聚合物系统。该材料有望提供更高的药物负荷，控制药物释放曲线，以及在支架寿命期间可调的机械性能。这将通过使用特定组合物的嵌段三元共聚物来完成，药物分子将共价附着在其上。DES技术的最新进展提高了冠心病治疗的成功率；然而，10%的植入支架发生再狭窄（通过支架再次阻塞动脉）。此外，目前可用的药物洗脱涂层在支架放置的前48小时内输送大部分负载药物，30天后几乎没有输送。因此，一种能够克服现有支架局限性的新型支架具有重要的应用价值。

This Small Business Innovation Research (SBIR) Phase I research research project aims to develop a polymer system for drug eluting coronary stents (DES). The material is expected to provide higher drug loading with a controlled drug release profile, as well as tunable mechanical properties over the lifetime of the stent. This will be accomplished using block terpolymers of specific composition to which drug molecules will be covalently attached. Recent advances in DES technology have increased the success rate of CHD treatment; however, restenosis (re-blockage of the artery through the stent) occurs in 10% of the implanted stents. Also currently available drug eluting coatings deliver the bulk of the loaded drug within the first 48 hours of stent placement, with little to no delivery after 30 days. Thus a new type of stent that can overcome the limitations of current stents would be of significant value.